Rystiggo, also known as ripponizumab, received its first approval on June 23, 2023 [1]. This approval was for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody-positive [1].
When can Rystiggo be prescribed?
Rystiggo's launch date followed closely after its approval. It became available for prescription in the United States shortly after June 23, 2023 [1].
What is Rystiggo used for?
Rystiggo is indicated for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies [1]. gMG is a rare, chronic autoimmune disease that causes weakness in the muscles that control breathing and other body movements [2].
How does Rystiggo work?
Rystiggo is a monoclonal antibody designed to target the neonatal Fc receptor (FcRn) [1]. By binding to FcRn, it prevents the recycling of immunoglobulin G (IgG) antibodies, leading to their degradation and thus reducing the levels of pathogenic IgG autoantibodies, including those that target the neuromuscular junction in gMG [3].
What are the potential side effects of Rystiggo?
The most common side effects reported for Rystiggo include urinary tract infections and diarrhea [1]. Patients should discuss potential risks and benefits with their healthcare provider.
How does Rystiggo compare to other gMG treatments?
Rystiggo is a novel immunotherapy option for gMG. Other treatment approaches for gMG include symptomatic therapies like cholinesterase inhibitors, as well as immunosuppressants and plasma exchange or intravenous immunoglobulin (IVIg) for more severe cases or during exacerbations [2]. The specific benefit of Rystiggo lies in its targeted mechanism of reducing pathogenic antibodies [3].
Who manufactures Rystiggo?
Rystiggo is developed by UCB Pharma [1].